ACTRN12620000745943
Not yet recruiting
Phase 4
The role of SGLT-2 inhibitors (Empagliflozin) in the management of glucocorticoid induced hyperglycaemia in adults with and without diabetes
Endocrinology Department, Gosford Hospital0 sites30 target enrollmentJuly 20, 2020
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Endocrinology Department, Gosford Hospital
- Enrollment
- 30
- Status
- Not yet recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion criteria
- •Informed consent
- •Adults aged 18 years old and older
- •Patients on Glucocorticoid therapy equivalent to 10mg prednisolone or more with planned duration of treatment for at
- •least 4 weeks
- •Patients without prior history of diabetes
- •Patients with pre\-existing diabetes on single agent metformin therapy
- •2 blood glucose readings measuring more than 10mmol/L within a 24 hour period OR
- •1 random blood glucose reading measuring more than 15mmol/L
Exclusion Criteria
- •Renal impairment eGFR less than 45ml/minute
- •Poor oral intake or patient on a low carbohydrate or ketogenic diet
- •Patient states that they are actively following a low carbohydrate diet which is
- •less than 130grams of carbohydrates a day
- •Patient states that they are actively following a ketogenic diet which is 20\-50grams of carbohydrates a day
- •Patient with active malignancy
- •History of recurrent genitourinary infections
- •Need for ICU admission at the time of recruitment
- •Current use of SGLT\-2 inhibitors
- •Acute CVA in the past 2/12
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Effect of SGLT2 inhibitor, canagliflozin, for the size of lipid particlesType 2 diabetesJPRN-UMIN000020027Tokyo Medical and Dental University Department of Medical Genetics / Gerontorgy30
Completed
Not Applicable
Influence of SGLT2-inhibitor (Canagliflozin) in patients with DM who underwent cardiac surgerypatients with diabetes mellitus underwent cardiac surgeryJPRN-UMIN000021239Sekino Hospital30
Active, not recruiting
Phase 1
SGLT2 inhibition with empagliflozin in patients with type 2 diabetes mellitus: Influences on left ventricular mass, function, and lipid content of myocardium (EMPATROPHY)Patients with type 2 diabetes mellitus on background metformin treatment.MedDRA version: 18.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2014-003313-28-DEHannover Medical School60
Not yet recruiting
Phase 3
Impact of empagliflozin on nephrolithiasis among patients without diabetes compared to a placebo in reduction in the number and/or size of renal stonesephrolithiasisSLCTR/2023/012Professorial Medical Unit
Recruiting
Phase 2
Effect of SGLT2 Inhibition With Empagliflozin on Atrial Fibrillation Severity (SWEET-AF)Atrial FibrillationCardiovascular - Other cardiovascular diseasesACTRN12621000208808The University of Adelaide300